Diseases
SELUTION DeNovo Trial Demonstrates Non-Inferiority of SELUTION SLR(DEB) to Standard of Care in De Novo Lesions
The largest randomized Drug Eluting Balloon trial, SELUTION DeNovo, has shown that a SELUTION SLR(TM) DEB treatment strategy is non-inferior to a systematic DES treatment strategy in real-world coronary de novo lesions. The trial, which enrolled 3,323 patients across 62 international sites, demonstrated a target vessel failure (TVF)